The FDA is clear on this, you can either:
1. Get excellent clinical efficacy results with no safety issues and they don't really care about replicating the mechanism of action in-vivo with in-vitro, or;
2.
Source: https://pink.citeline.com/-/media/supporting-documents/pink-sheet/2020/08/fda-briefing-document-on-remestemcel-l-am-session.pdf?rev=222f51497a0f49c294091e6ad844115c&hash=93D88D09ED488698D719E3EA21DD7334
- Forums
- ASX - By Stock
- CYP
- The Phase I/IIb Nereid Study Is Now Registered
The Phase I/IIb Nereid Study Is Now Registered, page-20
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
28.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $50.29M |
Open | High | Low | Value | Volume |
28.0¢ | 28.0¢ | 28.0¢ | $1.401K | 5.004K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 27.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.0¢ | 10182 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.275 |
1 | 1200 | 0.265 |
1 | 8000 | 0.255 |
2 | 22000 | 0.250 |
1 | 50000 | 0.235 |
Price($) | Vol. | No. |
---|---|---|
0.280 | 10182 | 1 |
0.285 | 5400 | 1 |
0.290 | 43500 | 2 |
0.295 | 51750 | 2 |
0.300 | 100000 | 1 |
Last trade - 15.59pm 17/05/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |